Cardiopulmonary Stress Testing Systems Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Cardiopulmonary Stress Testing Systems Market is Segmented by Product Type (Stress Blood Pressure Monitors, Stress ECG Systems, and More), End User (Specialty & Cardiology Clinics, and More), Application (Disease Diagnostics, Pre-Operative Risk Evaluation, and More), Technology (Treadmill-Based, and More), and Geography (North America, Europe, and More). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Cardiopulmonary Stress Testing Systems Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Cardiopulmonary Stress Testing Systems Market with other markets in Healthcare Industry

Cardiopulmonary Stress Testing Systems Market Analysis by Mordor Intelligence

The cardiopulmonary exercise testing market is valued at USD 5.80 billion in 2025 and is forecast to reach USD 5.86 billion by 2030, advancing at a 4.5% CAGR. Growth rests in the broader shift from volume-based diagnostics to precision cardiopulmonary evaluation, helped by AI-enabled real-time VO₂ analytics that shorten interpretation time and raise diagnostic consistency. Hospitals, sports laboratories, and rehabilitation centers also view these systems as strategic assets because early physiological insights reduce downstream treatment costs. Portable CPET platforms extend testing into home-based rehabilitation, while wearable sensors feed continuous data to cloud algorithms, linking disease diagnostics with fitness monitoring. North American reimbursement clarity, rising Asia-Pacific chronic-disease burden, and steady European clinical research activity collectively underpin demand for the expanding fleet of AI-ready devices. Meanwhile, mid-tier device makers face a regulatory maze that lengthens launch cycles, keeping bargaining power with hospitals moderate, even as user expectations for seamless workflow integration rise.

Key Report Takeaways

  • By product type, cardiopulmonary exercise-testing systems held 25.8% of the cardiopulmonary exercise testing market share in 2024, and the segment is growing fastest at 11.1% CAGR to 2030. 
  • By end user, hospitals captured 28.3% revenue in 2024, while sports-performance and research labs post the highest projected CAGR of 10.2% through 2030. 
  • By application, disease diagnostics commanded 25.2% of the cardiopulmonary exercise testing market size in 2024; sports and human-performance assessment is expanding at a 9.3% CAGR to 2030. 
  • By technology, treadmill-based stress testing generated 27.5% of 2024 revenues, whereas wearable and patch-based CPET systems are projected to rise at 10.3% CAGR. 
  • By geography, North America led with 29% revenue in 2024; Asia Pacific is advancing at an 8.5% CAGR through 2030.

Segment Analysis

By Product Type: CPET Systems Lead Innovation Wave

Cardiopulmonary exercise-testing systems generated 25.8% of 2024 revenue, and this category is pacing the field with 11.1% CAGR. The cardiopulmonary exercise testing market size linked to these systems will expand as integrated gas analyzers and stress ECG modules converge into touchscreen carts that auto-score data. Metabolic carts now self-calibrate in 90 seconds, reducing downtime. Meanwhile, stress blood-pressure monitors and entry-level ECG ergometers retain demand in clinics where budgets cannot yet stretch to full platforms. 

Algorithm-based interpretation cements this leadership: random-forest classifiers find mechanical-ventilatory bottlenecks that trainees might overlook, and automated ventilatory-threshold detection supports precise exercise prescriptions. Providers therefore prefer single-vendor bundles that cover cardiopulmonary exercise testing market compliance and remote-monitoring extensions in one purchase.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Sports Labs Drive Market Evolution

Hospitals controlled 28.3% expenditure in 2024, yet sports-performance and research labs headline growth at 10.2% CAGR, reflecting rising elite-fitness budgets and university studies. The cardiopulmonary exercise testing market benefits from pro-team demand for daily readiness scoring, and cycle-ergometer protocols fine-tuned to altitude camps. Rehabilitation centers follow suit, folding CPET into post-operative care plans reimbursed under newly expanded cardiac-rehab codes.

Unlike hospital procurement, sports facilities favor portability and rapid setup. Vendors are responding with backpack analyzers weighing under 400 g, Bluetooth-linked to tablets that parse breath-by-breath data through cloud AI, keeping the cardiopulmonary exercise testing market aligned with field-based applications while still compliant with clinical standards.

By Application: Disease Diagnostics Face Performance Assessment Challenge

Disease diagnostics retained 25.2% in 2024 and remains the anchor use case, yet sports and human-performance assessment is rising at 9.3% CAGR. Cardiac surgeons rely on pre-operative CPET when frailty assessment informs risk conversations. In ICUs, weaning protocols now reference exercise capacity recorded before admission. 

Conversely, collegiate athletics and corporate wellness programs adopt CPET to benchmark training efficacy, spurring vendors to add gamified dashboards. This interplay widens the cardiopulmonary exercise testing market as single platforms serve both pathological detection and peak-performance mapping, eliminating duplicate capital outlays.

Cardiopulmonary Stress Testing Systems Market: Market Share by Application
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Technology: Wearables Challenge Traditional Testing

Treadmill-based stress testing brought in 27.5% of revenue last year, but wearable and patch-based CPET devices show 10.3% CAGR, signaling decentralization. Pressure-sensing insoles, cuffless BP patches, and micro-ultrasound vests feed AI servers that compute equivalent VO₂ kinetics in real time. The cardiopulmonary exercise testing market size for wearables will thus climb quickly as hospitals prescribe home-monitoring kits to post-MI patients who cannot attend in-person sessions.

Tilt-table robotics retains a niche for syncope evaluation, and pharmacologic stress labs serve immobile patients, yet continuous ambulatory data increasingly supplement snapshots collected in those venues. This hybrid landscape cements the cardiopulmonary exercise testing market position as a cross-setting solution rather than a purely lab-based modality.

Geography Analysis

North America generated 29% of 2024 revenue. Adoption is buoyed by CMS rules that reimburse CPET for unexplained dyspnea, plus academic trials that bundle CPET endpoints into cardiovascular drug studies. GE Healthcare’s March 2025 release of Revolution Vibe CT illustrates the region’s appetite for AI-rich cardiology diagnostics that integrate seamlessly with CPET-derived risk scores. Canadian health networks invest in mobile units serving rural communities, broadening access while preserving provincial cost controls.

Asia Pacific is the fastest mover at 8.5% CAGR, propelled by chronic disease growth and hospital build-outs. China’s provincial tenders now stipulate VO₂max capability in county cardiac centers, while Japanese teaching hospitals employ CPET in oncology rehab pathways. India’s tier-two cities add dual-use CPET labs serving both clinical referrals and sports academies, further lifting cardiopulmonary exercise testing market penetration.

Europe maintains robust demand, helped by harmonised clinical guidelines that embed CPET into surgical clearance algorithms. Germany’s DiGA fast-track process incentivises vendors to pair CPET outputs with digital-therapeutic coaching apps, giving patients integrated post-test pathways. The UK National Health Service funds CPET slots in cardiac-rehab settings, citing reductions in unplanned readmissions. Southern Europe relies on EU structural funds to refresh metabolic-cart inventories, ensuring parity with northern centers.

Cardiopulmonary Stress Testing Systems Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The cardiopulmonary exercise testing market remains moderately fragmented. Top multinationals such as GE Healthcare, Philips and MGC Diagnostics deepen moats by embedding AI that simplifies interpretation workflows. GE’s purchase of the remaining stake in Nihon Medi-Physics in December 2024 broadened its reach in radiopharmaceutical-enabled cardiac imaging, a complement to CPET. Philips invests in ultrasound-based cardiac hemodynamics that can cross-link with VO₂ data streams to create unified cardiovascular dashboards.

Wearable-first entrants are tightening the race. Nanowear secured FDA clearance for its cuffless BP monitor that captures 85 biomarkers, offering a cheaper on-body surrogate to in-lab gas analysis for trend tracking. Start-ups leverage subscription software models, contrasting with capital-sale paradigms of incumbent cart manufacturers. Hospitals weigh these options against cybersecurity risk and integration complexity.

Strategic collaborations proliferate: GE Healthcare aligns with imaging-software houses to deliver non-invasive coronary flow ratios that dovetail with CPET stress protocols, while sports-tech brands partner with university labs for validation studies, thereby entering the clinical reimbursement chain. Patent portfolios around breath-sensor membranes and AI algorithms remain key differentiators that could trigger future consolidation.

Cardiopulmonary Stress Testing Systems Industry Leaders

  1. MGC Diagnostics Corporation

  2. General Electric Company

  3. Koninklijke Philips N V

  4. COSMED Srl

  5. Nihon Kohden Corp.

  6. *Disclaimer: Major Players sorted in no particular order
Cardiopulmonary Stress Testing Systems Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • March 2025: GE Healthcare launched Revolution Vibe CT with AI-powered one-beat cardiac imaging, improving workflow efficiency and reducing energy consumption.
  • December 2024: GE Healthcare acquired the remaining 50% of Nihon Medi-Physics, expanding its radiopharmaceutical footprint in Japan’s USD 7 billion molecular-imaging segment.
  • October 2024: MGC Diagnostics obtained FDA 510(k) clearance for Ascent software that unifies pulmonary-function and CPET assessment.
  • September 2024: GE Healthcare’s Flyrcado (flurpiridaz F 18) injection received FDA approval, enabling the combination of exercise stress testing with cardiac PET imaging.

Table of Contents for Cardiopulmonary Stress Testing Systems Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise In Global Healthcare Expenditure
    • 4.2.2 Rising Prevalence Of Cardiopulmonary Disorders
    • 4.2.3 Technological Advances In Stress-ECG & Metabolic Carts
    • 4.2.4 Favorable Reimbursement Policies For Diagnostic Testing
    • 4.2.5 AI-Enabled Real-Time VO? Analytics Adoption
    • 4.2.6 Home-Based Rehab Programs Needing Portable CPET Devices
  • 4.3 Market Restraints
    • 4.3.1 Stringent Multi-Region Device Approval Pathways
    • 4.3.2 High Capital & Lifecycle Costs Of Integrated CPET Labs
    • 4.3.3 Shortage Of Trained CPET Technologists
    • 4.3.4 Wearable Multiparametric Diagnostics Diverting Demand
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value)

  • 5.1 By Product Type
    • 5.1.1 Stress Blood-Pressure Monitors
    • 5.1.2 Stress ECG Systems
    • 5.1.3 Exercise Testing Systems
    • 5.1.4 Cardiopulmonary Exercise-Testing (CPET) Systems
    • 5.1.5 Metabolic Carts & Gas-Analysis Modules
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Specialty & Cardiology Clinics
    • 5.2.3 Ambulatory Surgical & Day-Care Centers
    • 5.2.4 Rehabilitation Centers
    • 5.2.5 Sports-Performance & Research Labs
  • 5.3 By Application
    • 5.3.1 Disease Diagnostics
    • 5.3.2 Pre-operative Risk Evaluation
    • 5.3.3 Cardiac & Pulmonary Rehabilitation
    • 5.3.4 Sports & Human-Performance Assessment
    • 5.3.5 Critical-Care & ICU Monitoring
  • 5.4 By Technology
    • 5.4.1 Treadmill-based Stress Testing
    • 5.4.2 Cycle-Ergometer-based Testing
    • 5.4.3 Robotics-Assisted Tilt-Table (RATT)
    • 5.4.4 Wearable / Patch-based CPET
    • 5.4.5 Pharmacologic Stress Testing Platforms
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia Pacific
    • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 GE Healthcare
    • 6.3.2 Koninklijke Philips N.V.
    • 6.3.3 COSMED Srl
    • 6.3.4 MGC Diagnostics Corp.
    • 6.3.5 Schiller AG
    • 6.3.6 Baxter (Q-Stress / Welch Allyn)
    • 6.3.7 Vyaire Medical
    • 6.3.8 Nihon Kohden Corp.
    • 6.3.9 Hillrom Holdings Inc.
    • 6.3.10 OSI Systems Inc.
    • 6.3.11 Allengers Medical Systems
    • 6.3.12 Cardioline SpA
    • 6.3.13 Morgan Scientific
    • 6.3.14 Geratherm Respiratory
    • 6.3.15 Vyntus (Vyaire)
    • 6.3.16 CareFusion (BD)
    • 6.3.17 Clarity Medical
    • 6.3.18 Innomed Medical
    • 6.3.19 CardioMed Treadmills
    • 6.3.20 Compumed Inc.
    • 6.3.21 Spacelabs Healthcare

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Cardiopulmonary Stress Testing Systems Market Report Scope

The cardiopulmonary stress test is an evaluation of the cardiopulmonary system that allows the physician to assess the functioning of the heart and lungs during exercise. The amount of oxygen consumed by a person while riding a bike or walking on a treadmill is used to assess various conditions like dyspnea, hypertrophic cardiomyopathy, and pulmonary hypertension.

 the cardiopulmonary stress testing systems market is segmented by product type (exercise testing systems, stress ECG, stress blood pressure monitors, and other product types), end user (hospitals, specialty clinics, ambulatory surgical centers, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD million) for the above segments.

By Product Type Stress Blood-Pressure Monitors
Stress ECG Systems
Exercise Testing Systems
Cardiopulmonary Exercise-Testing (CPET) Systems
Metabolic Carts & Gas-Analysis Modules
By End User Hospitals
Specialty & Cardiology Clinics
Ambulatory Surgical & Day-Care Centers
Rehabilitation Centers
Sports-Performance & Research Labs
By Application Disease Diagnostics
Pre-operative Risk Evaluation
Cardiac & Pulmonary Rehabilitation
Sports & Human-Performance Assessment
Critical-Care & ICU Monitoring
By Technology Treadmill-based Stress Testing
Cycle-Ergometer-based Testing
Robotics-Assisted Tilt-Table (RATT)
Wearable / Patch-based CPET
Pharmacologic Stress Testing Platforms
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific China
Japan
India
South Korea
Australia
Rest of Asia Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Product Type
Stress Blood-Pressure Monitors
Stress ECG Systems
Exercise Testing Systems
Cardiopulmonary Exercise-Testing (CPET) Systems
Metabolic Carts & Gas-Analysis Modules
By End User
Hospitals
Specialty & Cardiology Clinics
Ambulatory Surgical & Day-Care Centers
Rehabilitation Centers
Sports-Performance & Research Labs
By Application
Disease Diagnostics
Pre-operative Risk Evaluation
Cardiac & Pulmonary Rehabilitation
Sports & Human-Performance Assessment
Critical-Care & ICU Monitoring
By Technology
Treadmill-based Stress Testing
Cycle-Ergometer-based Testing
Robotics-Assisted Tilt-Table (RATT)
Wearable / Patch-based CPET
Pharmacologic Stress Testing Platforms
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific China
Japan
India
South Korea
Australia
Rest of Asia Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the cardiopulmonary exercise testing market?

The cardiopulmonary exercise testing market is valued at USD 5.80 billion in 2025.

How fast is the cardiopulmonary exercise testing market expected to grow?

The market is projected to expand at a 4.5% CAGR, reaching USD 5.86 billion by 2030.

Which product segment is growing the quickest within the cardiopulmonary exercise testing market?

Cardiopulmonary exercise-testing systems lead growth at an 11.1% CAGR through 2030.

What geographic region shows the highest growth rate for cardiopulmonary exercise testing solutions?

Asia Pacific posts the fastest regional expansion with an 8.5% CAGR between 2025 and 2030.

Page last updated on: June 29, 2025

Cardiopulmonary Stress Testing Systems Market Report Snapshots